<DOC>
	<DOCNO>NCT01811290</DOCNO>
	<brief_summary>The purpose study ass whether Multiple Sclerosis patient treat Gilenya show beneficial change time bone mass density bone turnover marker compare matched control treat alternative FDA approve therapy therapy .</brief_summary>
	<brief_title>A Pilot Study Assessing Impact Gilenya Therapy Bone Density Change Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description>To assess effect Gilenya rate decline bone mass density expression select bone turnover biomarkers ambulatory subject relapse form Multiple Sclerosis compare control subject match age , race , gender , duration disease , disability alternative FDA approve disease modify therapy therapy 24 month compare baseline .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>• Male female subject , 21 year age old . Subjects must able give consent sign date informed consent form ( write English ) prior study assessment perform . Ambulatory Expanded Disability Status Scale ( EDSS ) 2.5 6.5 inclusive . Must meet McDonald criterion relapse form ( relapse remit secondary progressive ) Multiple Sclerosis . Gilenya therapy group subject must treat Gilenya minimum 3 month uninterrupted prior screen visit , approve principal investigator continue agent . Control therapy group subject must consistently FDA approve disease modify therapy Gilenya therapy minimum 6 month prior screen visit . Subjects must neurologically stable receive form steroid therapy 4 week prior screen visit . Subjects must abide safety surveillance monitoring study appropriate disease modifying therapy consider standard care . Such monitoring consider outside scope study . Subjects must willing able comply protocol requirement duration study . • Subjects must treat Fingolimod , Gilenya experimental Sphingosine 1phosphate receptor agonist therapy clinical trial prior enrollment study . Subjects FDA approve disease modify therapy Gilenya , therapy , must receive Gilenya therapy within 12 month screen visit . Current previous use bisphosphonate therapy , estrogen replacement , calcitonin , DepoProvera , dehydroepiandrosterone , methotrexate within 12 month screen visit . Medical contraindication daily calcium intake least 1000 mg daily , vitamin D3 supplementation 800 IU daily . Vitamin D insufficiency ( 25hydroxy vitamin D level &lt; =30 ng/ml ) time baseline visit . Meeting National Osteoporosis Foundation criterion osteoporosis require treatment study prohibit therapy : History osteoporosis baseline Dexa bone scan T score &lt; 1.5 &gt; 2.0 one risk factor fracture ( age &gt; 50 year , current smoking , low Body Mass Index ( i.e . &lt; 18.5 ) , previous fragility fracture , parental history osteoporosis fragility fracture hip , femur , vertebra , alcohol consumption great 3 unit per day , daily glucocorticoid usage ) . Dexa bone scan T score &lt; 2.0 without additional risk factor . Subjects Body Mass Index &gt; =40 kg/m2 due artifact Body mass density measurement Dexa unit use . Subjects anatomical deformity vertebral fracture would potentially distort Body mass density measurement . Current diagnosis parathyroid disorder , untreated hyperthyroidism hypothyroidism , renal insufficiency ( Glomerular filtration rate ( GFR ) &lt; = 55 ) , history renal calculus stone , uncontrolled mood disorder , drug alcohol abuse . Current use `` first generation '' anticonvulsant medication ( barbiturate , phenytoin , carbamazepine , valproate ) , `` second generation '' anticonvulsant levetiracetam ( implicate recently accelerate bone density loss ) . Stable use `` second generation '' anticonvulsant medication ( gabapentin , pregabalin , lamotrigine , topiramate , lacosamide , zonisamide , oxcarbazepine ) symptoms management acceptable . Stable use dopamine reuptake inhibitor class , Serotonin Norepinephrine Reuptake Inhibitors , Selective serotonin reuptake inhibitor antidepressant therapy allow . Continuous `` pulsed '' treatment corticosteroid medical condition . Brief therapy intravenous methylprednisolone 1 gram 35 day oral taper , confirm neurological relapse allow . Subjects must unstable medical psychiatric condition per judgment principal investigator would risk safety completion study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>